Clinical Trial Update: Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model [Phase 1]

View source ↗

Summary

Phase 1 trial used eosinophilic esophagitis as a disease model to identify responders to omalizumab (Xolair); the study is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: O & O Alpan LLC | Conditions: Eosinophilic Esophagitis | Phase 1 | Status: COMPLETED